Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. - Wikidata - awgldk - TriplyDB

Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.

Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.

http://www.wikidata.org/entity/Q34414248

about

Treatment of Cancer Pain by Targeting Cytokines Diabetic neuropathic pain: Physiopathology and treatment Nociceptin and the nociceptin receptor in learning and memory The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates.Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain Central N/OFQ-NOP Receptor System in Pain Modulation.Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain.The use of opioids for treatment of cancer pain.Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.Hopes for the Future of Pain Control.Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.Challenges to develop novel anti-inflammatory and analgesic drugs.Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.Neuropathic Pain Treatment: Still a Challenge.Targeting multiple opioid receptors - improved analgesics with reduced side effects?Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.Limited potential of cebranopadol to produce opioid-type physical dependence in rodents.Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial.Changes in nociceptin/orphanin FQ levels in rat brain regions after acute and chronic cannabinoid treatment in conjunction with the development of antinociceptive tolerance.Towards an Effective Peripheral Visceral Analgesic: Responding to the National Opioid Crisis.Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic

P2860

Q26779917-48D04F22-9209-4968-8278-62A8D62FC36D Q27004604-69B1129B-C7CE-490D-9545-5A3D900F3B7B Q28257948-473FCF70-5FAE-4BDD-AFB6-3B588417ACCE Q30235088-3E30F464-6056-489D-8CF7-792B3D1FE64E Q33729139-B88D7C5B-825F-450F-8443-3BD8D0D08075 Q34434553-07641E2C-8B81-4C42-A5D3-3D2481594D40 Q35846195-0FD6D285-B33B-4FE4-8C2C-7F2B8B5BC3E1 Q36043728-474B342F-D60B-4408-B9D9-D4DDE34F88B3 Q36744366-72AD0EBB-60CA-4477-9FD8-F7E9BBE406C7 Q36849604-A53D6EEA-204F-42EB-B0D4-E5048879CB14 Q37094760-0F943A9D-5AC5-41BD-B398-66CEBB9FD574 Q37211503-D4172F4D-FF3C-4AAB-B15D-9057B1922C2D Q37264264-88C44A6B-B3F5-4F6D-B258-FD371AAD074F Q37340687-7EEA31B2-8B62-4064-8009-6887A57EED38 Q37591805-5FEEAE36-E7E3-4D15-A9D6-DC91E3332D01 Q37636107-B2548BED-E6C9-4702-8295-C0467D0B389A Q38281620-10E63721-A935-402A-A19C-BCAF5CEB19A8 Q38417418-8608B748-6B70-4033-9ADE-EEBD2FDE54E0 Q38679986-B6EE47E2-C6FA-42AC-A6EA-B6D389EA671E Q38721640-EFC0A49F-85F1-4DA8-A0AB-424CA478A0D2 Q38941483-8EE4F27F-9E11-4509-81C7-6F5A80AE44E4 Q38990121-29C762D8-4B5D-489B-B581-F2B23743C362 Q39169582-4463D307-0F6C-482D-A648-7AC352D97B72 Q39221109-19C29A23-5F1E-4E36-8C57-D07B3C53A55F Q43075530-E99DAFFA-53CF-467B-9AB1-F68A7DA32EA0 Q44341523-B1C2E396-100F-48A5-ADB3-B725C022273A Q44342818-5452A1A8-7845-449F-883B-D559C0E15BA7 Q44349177-7658E532-0078-4CF6-A8A2-85274CF2F30F Q44350191-0684885D-D104-417E-94D7-4B7900C500C2 Q44474417-E939CF9D-88C2-4C37-BA70-17A77A073914 Q47140416-BAE066AF-B6F7-4D36-A63B-636619C4D4E6 Q47717136-74A412EA-C6E7-4BBE-BC2D-A96E87A4E2A4 Q48643943-95E70331-FC69-4D59-B74D-C0AD64678990 Q52315691-E6C7B496-FEB3-4723-9F7F-4BA368982DF8 Q58545262-7EC24318-F535-4C9A-8075-5F571DDA4B9C

P2860

Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.

http://www.wikidata.org/entity/Q34414248

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@ast

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@en

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@nl

type

label

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@ast

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@en

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@nl

prefLabel

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@ast

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@en

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@nl

P1433

Q34414248-2FB48C13-1220-466D-A870-944637D83BDF

P1476

Q34414248-DEC0A8A8-C256-4150-8503-6AED55AAA732

P2093

Q34414248-26A9AA19-A14A-48CF-BD97-22CB32E99D18

Q34414248-311F37B0-97F3-4318-AD91-432F8454216B

Q34414248-47DFE573-8CDC-4522-8E28-6E0D7E7F8E28

Q34414248-4DD5706B-AE2F-43C9-80B3-3730668B43EF

Q34414248-69023384-2E05-4BB0-92F0-E28CB5476219

Q34414248-77A1853A-585B-4256-A0DC-D26D2A76B108

Q34414248-7DDB5F5C-9105-4F62-A556-A69F96E533E2

Q34414248-94B5BB10-3856-45DC-8C87-BC771535A40A

Q34414248-9C8B819D-0410-4C99-BD37-CFAA457355A4

Q34414248-9D840C44-69D7-4BB6-A8F7-FAA1D4F0F40E

P304

Q34414248-22A77B2F-EF68-49F3-802C-4194FAB44F58

P31

Q34414248-82EF14B0-F41B-4AE1-816C-5EC32DC9DA61

P356

Q34414248-E425C136-EE72-4C2D-8210-18959FC28EDE

P407

Q34414248-85F755D4-F830-4533-9D73-A41CDF6BD5F3

P433

Q34414248-9AA3F3CB-E88F-4561-BECF-8087286BBE37

P478

Q34414248-EB350785-340F-4F01-B217-82DD0766799C

P50

Q34414248-34373117-EF77-4207-BDA5-283A3DD9A01E

P577

Q34414248-D911578C-94C3-41B4-A5AC-57CDAFD21720

P5875

Q34414248-7BE0778F-F7DD-4AF7-91B3-3E2E8F8C69A7

P698

Q34414248-1C8685D6-0A11-4C8D-9864-1A3B8CADE615

P921

Q34414248-27f8ef8c-9413-4cd0-aeca-66807e4b9e5d

Q34414248-653045f3-e4c6-4e0d-91b4-2ab7307687e1

P356

JPET.114.213694

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Cebranopadol: a novel potent a ...... e and opioid receptor agonist.

@en

P2093

Babette Y Kögel

http://www.w3.org/2001/XMLSchema#string

Horst Beier

http://www.w3.org/2001/XMLSchema#string

Jean De Vry

http://www.w3.org/2001/XMLSchema#string

Klaus Linz

http://www.w3.org/2001/XMLSchema#string

Klaus Schiene

http://www.w3.org/2001/XMLSchema#string

Michael Gautrois

http://www.w3.org/2001/XMLSchema#string

Stefan Schunk

http://www.w3.org/2001/XMLSchema#string

Stefanie Frosch

http://www.w3.org/2001/XMLSchema#string

Thomas Christoph

http://www.w3.org/2001/XMLSchema#string

Thomas Koch

http://www.w3.org/2001/XMLSchema#string

P304

535-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.114.213694

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang Schröder

P577

2014-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261515329

http://www.w3.org/2001/XMLSchema#string

P698

24713140

http://www.w3.org/2001/XMLSchema#string

P921